ESC Premium Access

Elevated markers of liver function are associated with poorer outcomes in HFREF: an analysis of DAPA-HF

Presentation

About the speaker

Ms Lorna Cowan

Glasgow (United Kingdom of Great Britain & Northern Ireland)
0 follower

218 more presentations in this session

Intermittent therapy with levosimendan in patients with advanced heart failure

Speaker: Professor M. Weis (Munich, DE)

Thumbnail

Differences in long-term all-cause and cardiovascular mortality according to heart failure aetiology in ambulatory patients

Speaker: Doctor G. Spitaleri (Badalona, ES)

Thumbnail

Comparing the central arterial stiffness indices in the decompensated and compensated states of heart failure: a cohort study

Speaker: Assistant Professor G. Youssef (Cairo, EG)

Thumbnail

Opportunities for clinician education in the pharmacotherapy of stable heart failure

Speaker: Doctor P. Murray (Dublin, IE)

Thumbnail

Systolic blood pressure visit-to-visit variability and clinical outcomes of heart failure with preserved ejection fraction

Speaker: Doctor Q. Zhang (Tianjin, CN)

Thumbnail

Access the full session

Chronic heart failure e-posters

Speakers: Ms L. Cowan, Professor M. Weis, Doctor G. Spitaleri, Assistant Professor G. Youssef, Doctor P. Murray...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Choosing wisely: ablation or medication for rhythm control in atrial fibrillation – discussion.

27 August 2021

ESC Premium Access

The role of modifiable risk factors for the maintenance of sinus rhythm in the atrial fibrillation patient.

27 August 2021

ESC Premium Access

Ablation or amiodarone for HFrEF patients with atrial fibrillation?

27 August 2021

This platform is supported by

logo Novo Nordisk